aTyr Pharma Inc expected to post a loss of 23 cents a share - Earnings Preview

aTyr Pharma

11/03/2025 20:09

aTyr Pharma Inc ATYR.OQ ATYR.O is expected to show a rise in quarterly revenue when it reports  results on March 13 for the period ending December 31 2024

The San Diego California-based  company is expected to report revenue of $11.11 thousand, according to the mean estimate from 9 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for aTyr Pharma Inc is for a loss of 23 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for aTyr Pharma Inc is $16.00‚Äč, above‚Äč its last closing price of $3.10. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.22
-0.22
-0.23
Missed
-4.5
Jun. 30 2024
-0.24
-0.24
-0.23
Beat
3.4
Mar. 31 2024
-0.25
-0.24
-0.23
Beat
2.5‚Äč
Dec. 31 2023
-0.24
-0.25
Missed
-5
‚Äč‚ÄčSep. 30 2023
-0.22
-0.23
-0.20
Beat
11.5
Jun. 30 2023
-0.28
-0.28
-0.22
Beat
21‚Äč
Mar. 31 2023
-0.40
-0.40
-0.29
Beat
27.2
Dec. 31 2022
-0.48
-0.48
-0.26
Beat
45.8

This summary was machine generated March 11 at 20:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)